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Since cognitive deterioration is one of the core 
symptoms of depression and the immune system, 
particularly an infl ammatory process is increasingly 
discussed to be involved in the pathophysiology of de-
pression,, a role of the immune system in cognition 
came into the focus of research. Interestingly, several 
studies show in the meanwhile a strong involvement 
of the immune system in cognition. In infl ammation, 
proinfl ammatory cytokines as part of the immune sys-
tem are activated. An overactivation of proinfl amma-
tory cytokines, such as IL-6, IL-1 and TNF-a plays 
a role in depression. Th e term ‘infl ammaging’ refl ects 
the increasing pro-infl ammatory immune state during 
aging, but it has also been shown that the blood-con-
centration of proinfl ammatory proteins such as Inter-
leukin-6 (IL-6) and haptoglobin predict the cognitive 
performance three and six years later in aged people. 
In an animal model, the intact T-cell response was 
shown to be the pre-condition for a better cognitive 
performance. Th e recently published Whitehall II 
study showed that the concentrations of C-reactive 
protein and IL-6 were predictive for cognitive symp-
toms of depression after 12 years.
Accordingly, anti-infl ammatory or immunomodu-
latory therapy would be expected to enhance cognitive 
performance. Up to now there are only few data fo-
cussing on the infl uence of those compounds to cog-
nition. In Alzheimer’s disease, there have been stud-
ies with disappointing results. An own study using 
the cyclo-oxygenase-2 (COX-2) inhibitor celecoxib 
showed therapeutic eff ects on cognitive symptoms in 
patients with schizophrenia. COX-2 inhibition reduc-
es the levels of proinfl ammatory cytokines. Th e results 
and consequences of these data will be discussed.
